FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4206660037> ?p ?o ?g. }

• W4206660037 abstract "Objective: To study the virological and serological indicators before treatment and 24 weeks after treatment to predict the partial virological response (PVR) of 48-week entecavir (ETV) treatment, and formulate early clinical adjustment treatment plans for HBeAg-positive CHB patients. Methods: HBeAg-positive CHB-naïve patients diagnosed in the Department of Infectious Diseases, Shengjing Hospital, China Medical University, who were treated with oral ETV monotherapy from January 2018 were enrolled. The groups were divided according to the test results of HBV DNA at 48 weeks. Among them, HBV DNA < 20 IU/ml was the complete viral response (CVR) group, and HBV DNA ≥ 20 IU/ml was the PVR group. The virological and serological indexes of the two groups before treatment and 24 weeks after treatment were compared. ROC curve univariate analysis and multivariate logistic regression were performed to find out the early predictors of PVR in HBeAg-positive CHB patients receiving ETV therapy for 48 weeks. Results: As of July 2020, a total of 90 cases had completed 48 weeks of treatment, including 50 cases of CVR (55.56%) and 40 cases of PVR (44.44%). Before treatment and at 24 weeks of treatment, HBsAg, HBeAg and HBV DNA in the PVR group were significantly higher than those in the CVR group (P < 0.001). Univariate analysis showed that HBV DNA quantification (AUC = 0.961, P < 0.001, PPV = 97.06%, NPV = 87.50%) and HBeAg quantification (AUC = 0.883, P < 0.001, PPV = 90.63%, NPV = 81.03%) had higher predictive value at 24 weeks of treatment. Multivariate analysis showed that HBeAg > 1.952 log(10) S/CO (OR = 3.177, 95% CI: 1.261 ~ 8.267, P = 0.018) and HBV DNA > 2.205 log(10) IU / ml (OR = 43.197, 95% CI: 6.858 ~ 272.069, P < 0.001) were independent predictors of PVR at 24 weeks of treatment, and their combination had the best predictive effect. Conclusion: In HBeAg-positive CHB patients receiving ETV treatment for 48 weeks, HBV DNA combined with HBeAg quantification can be an early predictor of PVR at 24 weeks. Additionally, patients with both HBV DNA and HBeAg > 2 log(10) at 24 weeks of treatment must wait 48 weeks to obtain CVR, so it is recommended that treatment strategies should be adjusted at this time.目的： 恩替卡韦(ETV)治疗HBeAg阳性慢性乙型肝炎（CHB）48周不完全病毒学应答(PVR)比例越来越高，此时调整治疗策略会给部分患者带来临床不良结局的风险。采用治疗前及治疗后24周病毒学和血清学指标，预测HBeAg阳性CHB患者应用ETV治疗48周PVR，指导临床早期调整治疗方案。 方法： 入组患者：2018年1月起开始在中国医科大学附属盛京医院感染科诊断的HBeAg阳性CHB初治患者，口服ETV单药治疗。根据48周HBV DNA检测结果进行分组，其中HBV DNA < 20 IU/ml为完全病毒应答(CVR)组、HBV DNA≥20 IU/ml为PVR组。比较两组治疗治疗前及治疗后24周病毒学及血清学指标，进行ROC曲线单因素分析和多因素logistic分析，找出预测HBeAg阳性CHB患者应用ETV治疗48周PVR的早期预测指标。 结果： 截止到2020年7月共计90例患者完成48周治疗，其中CVR 50例(55.56%)，PVR 40例(44.44%)。PVR组治疗前及治疗24周HBsAg、HBeAg、HBV DNA均明显高于CVR组(P < 0.001）；单因素分析显示治疗24周HBV DNA定量(AUC = 0.961，P < 0.001；PPV = 97.06%，NPV = 87.50%)和HBeAg定量（AUC = 0.883，P < 0.001；PPV = 90.63%，NPV = 81.03%）的预测价值较高；多因素分析显示治疗24周HBeAg > 1.952 log(10) S/CO（OR = 3.177，95% CI：1.261～8.267，P = 0.018）和HBV DNA > 2.205 log(10) IU/ml (OR = 43.197，95% CI：6.858～272.069，P < 0.001)是PVR的独立预测指标，二者联合预测效果最好。 结论： 治疗24周HBV DNA联合HBeAg定量可以早期预测ETV治疗HBeAg阳性CHB患者ETV治疗48周PVR；治疗24周HBV DNA和HBeAg均> 2 log(10)的患者继续治疗至48周均不能获得CVR，建议此时应该调整治疗策略。." @default.
• W4206660037 created "2022-01-26" @default.
• W4206660037 creator A5033122116 @default.
• W4206660037 creator A5045190307 @default.
• W4206660037 creator A5052123695 @default.
• W4206660037 creator A5066251595 @default.
• W4206660037 creator A5076577662 @default.
• W4206660037 date "2020-12-20" @default.
• W4206660037 modified "2023-10-16" @default.
• W4206660037 title "[Study on early predictive factors of an incomplete viral response with 48 week-entecavir therapy in HBeAg-positive chronic hepatitis B patients]." @default.
• W4206660037 doi "https://doi.org/10.3760/cma.j.cn501113-20200907-00505" @default.
• W4206660037 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34865347" @default.
• W4206660037 hasPublicationYear "2020" @default.
• W4206660037 type Work @default.
• W4206660037 citedByCount "0" @default.
• W4206660037 crossrefType "journal-article" @default.
• W4206660037 hasAuthorship W4206660037A5033122116 @default.
• W4206660037 hasAuthorship W4206660037A5045190307 @default.
• W4206660037 hasAuthorship W4206660037A5052123695 @default.
• W4206660037 hasAuthorship W4206660037A5066251595 @default.
• W4206660037 hasAuthorship W4206660037A5076577662 @default.
• W4206660037 hasConcept C126322002 @default.
• W4206660037 hasConcept C144301174 @default.
• W4206660037 hasConcept C151956035 @default.
• W4206660037 hasConcept C159654299 @default.
• W4206660037 hasConcept C203014093 @default.
• W4206660037 hasConcept C2522874641 @default.
• W4206660037 hasConcept C2775940106 @default.
• W4206660037 hasConcept C2776175608 @default.
• W4206660037 hasConcept C2777382497 @default.
• W4206660037 hasConcept C2777410769 @default.
• W4206660037 hasConcept C2777869810 @default.
• W4206660037 hasConcept C2780593183 @default.
• W4206660037 hasConcept C3020491458 @default.
• W4206660037 hasConcept C38180746 @default.
• W4206660037 hasConcept C45189115 @default.
• W4206660037 hasConcept C71924100 @default.
• W4206660037 hasConcept C90924648 @default.
• W4206660037 hasConceptScore W4206660037C126322002 @default.
• W4206660037 hasConceptScore W4206660037C144301174 @default.
• W4206660037 hasConceptScore W4206660037C151956035 @default.
• W4206660037 hasConceptScore W4206660037C159654299 @default.
• W4206660037 hasConceptScore W4206660037C203014093 @default.
• W4206660037 hasConceptScore W4206660037C2522874641 @default.
• W4206660037 hasConceptScore W4206660037C2775940106 @default.
• W4206660037 hasConceptScore W4206660037C2776175608 @default.
• W4206660037 hasConceptScore W4206660037C2777382497 @default.
• W4206660037 hasConceptScore W4206660037C2777410769 @default.
• W4206660037 hasConceptScore W4206660037C2777869810 @default.
• W4206660037 hasConceptScore W4206660037C2780593183 @default.
• W4206660037 hasConceptScore W4206660037C3020491458 @default.
• W4206660037 hasConceptScore W4206660037C38180746 @default.
• W4206660037 hasConceptScore W4206660037C45189115 @default.
• W4206660037 hasConceptScore W4206660037C71924100 @default.
• W4206660037 hasConceptScore W4206660037C90924648 @default.
• W4206660037 hasLocation W42066600371 @default.
• W4206660037 hasOpenAccess W4206660037 @default.
• W4206660037 hasPrimaryLocation W42066600371 @default.
• W4206660037 hasRelatedWork W11731840 @default.
• W4206660037 hasRelatedWork W13569999 @default.
• W4206660037 hasRelatedWork W13787941 @default.
• W4206660037 hasRelatedWork W15199039 @default.
• W4206660037 hasRelatedWork W16607063 @default.
• W4206660037 hasRelatedWork W18895069 @default.
• W4206660037 hasRelatedWork W4310718 @default.
• W4206660037 hasRelatedWork W4980254 @default.
• W4206660037 hasRelatedWork W7617068 @default.
• W4206660037 hasRelatedWork W4638229 @default.
• W4206660037 isParatext "false" @default.
• W4206660037 isRetracted "false" @default.
• W4206660037 workType "article" @default.